Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...
Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...
Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug ...
GlobalData on MSN5d
ESMO 2024: Exact Sciences unveils results from cancer algorithm trialThe results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback